GlaxoSmithKline Expands Portfolio of Medicines in the U.S. for Patients with Asthma and COPD
January 28, 2015 |
January 28, 2015- GlaxoSmithKline(GSK) has announced the availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the United States.
Arnuity™ Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma and Incruse® Ellipta® (umeclidinium bromide) is an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
For more information, read the full release here.